+ Watch PATH
on My Watchlist
This red thumb could make me look dumb in the short term if NuPathe were to announce a Zecuity partnership, which certainly isn't outside the realm of possibility. Nevertheless, it's hard to imagine partnership terms which will change the fact that NuPathe has only 10M cash and is spending way too much money considering that they are not running any advanced clinical trials nor preparing for a product launch. In fact, at this point I can't see why any potential partner wouldn't simply wait for NuPathe to run out of money and options and then buy Zecuity out of bankruptcy.If NuPathe is able to get a partner, expect the stock to double overnight and then fizzle once the street realizes that the partnership terms still require another destructive dilutive financing for NuPathe to remain solvent. Remember the last one? Shudder.
Hoping the FDA approves their migraine patch, Zelrix.
IPO that has been battered badly with low volume but catalyst events coming up in December. Low float and decent fundamentals.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions